



November 3, 2015

TransEnterix, Inc. Appoints Steven Boudrez as Vice President of Sales, Europe

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that Steven Boudrez, an experienced robotic surgery sales executive, has been appointed as Vice President of Sales, Europe. Mr. Boudrez will report directly to TransEnterix's CEO, Todd M. Pope.

"We are pleased to announce Steven's appointment as the Vice President of Sales, Europe," said Todd M. Pope, Chief Executive Officer of TransEnterix. "As we prepare to immediately commercialize the ALF-X Surgical Robot in multiple countries that accept CE Mark, it was our top priority to bring someone on board who has both a deep understanding of the European market and the surgical robotics industry. We believe Steven's significant experience and track record will be invaluable to our successful sales execution."

Mr. Boudrez joins TransEnterix with nearly 20 years of experience in medical technology sales in the European market - of which 13 years were spent in leadership positions in the surgical robotics industry. He most recently served as Vice President of Sales, Europe at MedTech S.A., a robotic neurosurgery company. Prior to joining MedTech, Mr. Boudrez worked at Intuitive Surgical, Inc. for over 12 years in leadership positions of increasing responsibility in both clinical and capital sales. He most recently served as Sales Director, where he oversaw sales execution in France, Switzerland, Belgium, the Netherlands and Luxembourg. During his time at Intuitive, Mr. Boudrez successfully drove robotic system placements in markets under his responsibility from 2 to over 160, and grew the clinical and capital sales teams from 3 to 50. Before joining Intuitive Surgical, Mr. Boudrez held a sales position at Johnson & Johnson, Ethicon Endo-Surgery. Mr. Boudrez received dual-master's degrees from the University of Gent in Belgium.

"After spending the majority of my career selling surgical robotics platforms, I realize the significant opportunity that now exists for a system that addresses limitations of current robotics while delivering responsible economics," said Boudrez. "I look forward to joining the leadership of TransEnterix and building a team of experienced sales professionals to drive our results in Europe."

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform, and the commercialization of ALF-X®, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not yet available for sale in any market. The ALF-X has been granted a CE Mark but is not available for sale in the US. For more information, visit the TransEnterix website at www.transenterix.com.

Forward-Looking Statements

This press release includes statements relating to the ALF-X® System and our current regulatory and commercialization plans. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations, including whether Mr. Boudrez's experience and track record will result in successful sales execution in Europe. For a discussion of the most significant risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q filed on August 6, 2015 and other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](http://www.businesswire.com/news/home/20151103005305/en/): <http://www.businesswire.com/news/home/20151103005305/en/>

TransEnterix, Inc.

Investor:

Westwicke Partners

Mark Klausner, 443-213-0501
transenterix@westwicke.com

or

Media:

Mohan Nathan, 919-917-6559
mnathan@transenterix.com

Source: TransEnterix, Inc.

News Provided by Acquire Media